Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
| ▸ | KHK | P50053 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9558262 | 0.87 | HTR6 (0.68) | HTR6KHKHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL1400723 | 0.87 | HTR6 (0.56) | HTR6KHKHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL21094077 | 0.86 | HTR6 (0.57) | HTR6KHK | |
| SCHEMBL31208620 | 0.82 | HTR6 (0.56) | HTR6KHKHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL29316993 | 0.82 | HTR6 (0.56) | HTR6KHKHTR2CHTR2B | |
| SCHEMBL24684499 | 0.79 | HTR6 (0.70) | HTR6KHKHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL4466359 | 0.79 | HTR6 (0.59) | HTR6KHKHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL19217231 | 0.78 | HTR6 (0.42) | HTR6KHKHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL4821430 | 0.78 | HTR6 (0.45) | HTR6KHKHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL238942 | 0.78 | HTR6 (0.75) | HTR6KHKHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190177288-A1 | INTERMEDIATES AND PROCESS FOR PREPARING INTERMEDIATES IN THE PRODUCTION OF SUBSTITUTED PYRAZOLOPYRIDINES | ADVERIO PHARMA GMBH (DE) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177288-A1 | INTERMEDIATES AND PROCESS FOR PREPARING INTERMEDIATES IN THE PRODUCTION OF SUBSTITUTED PYRAZOLOPYRIDINES | CYP3A5, CYP4F2, CYP2F1 | HTR6 1693/4885KHK 182/4885HPGD 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.